Different effects of aliskiren and losartan on fibrinolysis and insulin sensitivity in hypertensive patients with metabolic syndrome

R. Fogari, A. Zoppi, A. Mugellini, P. Lazzari, G. Derosa

Research output: Contribution to journalArticle

Abstract

The aim of this study was to compare the effect of aliskiren and losartan on fibrinolysis and insulin sensitivity (IS) in hypertensive patients with metabolic syndrome. After 2-week placebo period, 76 outpatients with mild to moderate hypertension and metabolic syndrome were randomized to aliskiren 300mg od or losartan 100mg od for 12 weeks. Clinic blood pressure (BP), plasma PAI-1 antigen, and tPA activity were evaluated after 2, 4, 8, and 12 weeks of treatment. At the end of each treatment period patients performed an euglycemic hyperinsulinemic clamp and IS was assessed by glucose infusion rate (GIR). Both aliskiren and losartan induced a significant and similar SBP/DBP reduction (-15.6/10.7mmHg and -15.5/10.5mmHg, p

Original languageEnglish
Pages (from-to)892-896
Number of pages5
JournalHormone and Metabolic Research
Volume42
Issue number12
DOIs
Publication statusPublished - 2010

Keywords

  • AT1R blockers
  • PAI-1 antigen
  • renin inhibition
  • tPA activity

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Different effects of aliskiren and losartan on fibrinolysis and insulin sensitivity in hypertensive patients with metabolic syndrome'. Together they form a unique fingerprint.

  • Cite this